SciSparc Completes Endoscope IP Acquisition, Issues Highly Dilutive Warrants

summarizeSummary

SciSparc Ltd. has finalized the acquisition of an endoscope IP portfolio from Xylo Technologies Ltd., issuing pre-funded warrants representing 19.99% of its outstanding shares to advance into the multi-billion dollar GERD device market.

check_boxKey Events

• Acquisition Completed

  SciSparc Ltd. successfully closed the acquisition of a complete portfolio of patents, trademarks, know-how, and related intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd.

• Significant Dilution via Warrants

  In consideration for the acquired assets, SciSparc issued pre-funded warrants to Xylo Technologies Ltd. to purchase 1,017,391 ordinary shares at a nominal exercise price of $0.001 per share. These warrants represent 19.99% of SciSparc's issued and outstanding share capital.

• Strategic Commercialization Focus

  The company intends to commence immediate commercialization of these patented technologies, targeting the global GERD device market, which was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.

• Replicating Proven Model

  SciSparc aims to replicate Xylo's successful licensing and distribution model, previously established in Greater China, across high-growth territories such as North America, Europe, and Latin America.

auto_awesomeAnalysis

This filing announces the successful closing of SciSparc's acquisition of an endoscope IP portfolio from Xylo Technologies Ltd., an event previously disclosed on January 13, 2026. The acquisition includes the MUSE™ system, an innovative endoscopic device for treating gastroesophageal reflux disease (GERD), a market projected to reach over $3 billion by 2030. While the acquisition provides a clear path to immediate commercialization and potential revenue generation, the consideration involved the issuance of pre-funded warrants representing a substantial 19.99% of SciSparc's outstanding share capital. This significant dilution, especially for a micro-cap company trading near its 52-week low and recently receiving a Nasdaq non-compliance notice, balances the positive strategic implications of entering a large new market. Investors should monitor the company's execution of its commercialization strategy and its ability to secure licensing and distribution partnerships to leverage this new asset, as this move appears to be a critical step towards generating new revenue streams and addressing its financial position.